Business
Theralase Provides Update on Voting Procedures for Shareholder Meeting
TORONTO, ON / ACCESSWIRE / September 24, 2020 / Theralase® Technologies Inc. (" The...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase Provides Update on Voting Procedures for Shareholder MeetingTORONTO, ON / ACCESSWIRE / September 24, 2020 / Theralase® Technologies Inc. (\"Theralase\" or \"Company\") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDC\") and associated drug formulations, provides clarification on how registered shareholders or duly appointed proxyholders who plan to attend the Company's virtual Annual General and Special Meeting (\"Meeting\") at 4:30pm EDT today can cast their vote at the Meeting.Only registered shareholders of record as of the close of business on August 21, 2020, the record date for the Meeting, or their duly appointed proxyholders, will be entitled to vote at the virtual Meeting. Shareholders of record and duly appointed proxyholders must, prior to the start of the Meeting (1) access the Meeting by connecting through the link set out below, and (2) connect via phone using the dial-in number set out below in order to be able to vote their shares at the Meeting.Note: If a registered shareholder has voted their shares online, they do not need to vote them again. The opportunity to vote at the Meeting is only if they wish to change the way their shares are voted.Access via the following link:https://78449.themediaframe.com/dataconf/productusers/ther/mediaframe/40318/indexl.htmlANDDial-in using either of these phone numbers: 1-877-407-8037 (toll-free) or (201) 689-8037 (toll)In terms of the voting procedure, all confirmed registered shareholders and duly appointed proxyholders in attendance via live webcast and teleconference will be able to vote their shares by pressing *1 on their telephones on each of the matters tabled at the Meeting, as will be further explained at the start of the Meeting.Each registered shareholder or duly appointed proxyholder is entitled to one vote for each common share held as of the close of business on the record date of August 21, 2020.About Theralase® Technologies Inc.Theralase® is a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds and their associated drug formulations intended to safely and effectively destroy various cancers, bacteria and viruses.Additional information is available at www.thera...